The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 38.50
Bid: 38.00
Ask: 39.00
Change: 2.00 (5.48%)
Spread: 1.00 (2.632%)
Open: 37.00
High: 40.50
Low: 36.75
Prev. Close: 36.50
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: CleanTech raises GBP520,000 in open offer

Thu, 14th Dec 2023 20:20

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company, focused on developing kinase inhibitors to treat autoimmune diseases and cancer - Says it is optimistic about its pipeline, as its focus remains on advancing its SDC-1801 therapy. Notes that it expects to receive full safety data for SDC-1801 in the first half of 2024. Says it intends to begin a phase 2 study, which will be completed by the end of 2024.

----------

Ethernity Networks Ltd - Israel-based supplier of data processing semiconductor technology for networking appliances - Says it has received a request from 5G Innovation Leaders Fund LLC to issue 61.5 million new shares pursuant to its settlement deed. In November, it issued 44.9 million shares. Says that following the issue, it will have completed its obligations. Says the new shares to be admitted will represent 21% of its issued capital.

----------

Ashoka WhiteOak Emerging Markets Trust PLC - investment trust focused on global emerging markets - Says net asset value total return for period from its IPO in May to September 30 was 2.60%, outperforming its MSCI Emerging Markets Net Return Sterling by 1.2%. Notes that its share price is performing at a 2.2% premium to NAV. Notes that its key drivers of growth were Senco Gold, Gokaldas Exports and DBS Group. Chair Martin Shenfield says: "We are delighted to present our initial Interim Report covering the period to 30 September 2023 which included the company's successful listing on the London Stock Exchange, a landmark IPO for the sector considering the significant drought of new listings in recent years. We retain the conviction outlined at the company's IPO that the investment case for emerging markets remains attractive and that the company's bottom-up investment strategy provides a highly differentiated approach to accessing this key investment theme with the objective of generating outperformance over the long term."

----------

Digital 9 Infrastructure PLC - invests in internet infrastructure, such as data centres and subsea fibre - Says it has appointed Charlotte Valeur as its interim chair. Notes that its sale of Verne Global is on track to be completed by the end of the first quarter of 2024. Valeur comments: "We remain committed to completing the sale of Verne Global and expediting the strategic review to further maximise shareholder value".

----------

CleanTech Lithium PLC - Chile-focused lithium exploration and development - Says its open offer closed for acceptances oversubscribed by 13% at GBP586,000. Notes it was required to scale back its valid applications to its maximum allowance of 2.4 million, raising a total of GBP520,000. Says it has raised a total of GBP8.5 million from its open offer and fundraising programme. Chief Executive Aldo Boitano says: "Thank you to all our shareholders who participated in the recent open offer and to those who voted at our general meeting. It is encouraging to see an active investor base and your continued support is much appreciated as we develop sustainable lithium projects in Chile. I am particularly pleased that our open offer was oversubscribed, a clear vote of confidence for the company's plans in 2024."

----------

By Harvey Dorset, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
31 May 2018 12:17

Sareum Regains Worldwide Rights To Leukaemia Treatment

LONDON (Alliance News) - Sareum Holdings PLC said on Thursday that it has regained its worldwide rights to a potential treatment for leukaemia and other blood-related cancers.The drug said

Read more
15 Mar 2018 13:55

Sareum Partner Sierra Oncology To Present Positive SRA737 Results

LONDON (Alliance News) - Sareum Holdings PLC said Thursday its development partner Sierra Oncology's SRA737 results have been accepted for presentation at the annual of of

Read more
9 Jan 2017 16:39

Sareum Holdings receives milestone payment

(ShareCast News) - Sareum Holdings, an AIM listed specialist cancer drug discovery and development company, has announced the attainment of a $2m milestone payment as part of the Chk1 license agreement between its co-investment partner the CRT Pioneer Fund and Sierra Oncology, formerly known as ProN

Read more
9 Jan 2017 12:19

Sareum To Receive USD550,000 From Joint Licence Success Payment

Read more
24 Oct 2016 15:02

Sareum reports positive results from TYK2 programme

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced a successful conclusion from its feasibility study into the potential for its TYK2 programme lead molecules to treat T-Cell Acute Lymphoblastic Leukaemia (T-ALL) on Monday. The AIM-traded company said the i

Read more
24 Oct 2016 08:13

Sareum Welcomes Positive Feasibility Results For Leukemia Treatment

Read more
17 Oct 2016 14:16

Sareum Holdings granted patents in Japan and Singapore

(ShareCast News) - Specialist cancer drug discovery and development company Sareum announced on Monday that the Japan and Singapore Patent Offices have issued notifications that patents will be granted for inventions associated with its Aurora+FLT3 kinase inhibitor programme. The AIM-traded firm sai

Read more
27 Sep 2016 11:13

Sareum Holdings Co-Investment Partner Inks Licence Agreement

Read more
3 Aug 2016 14:56

Sareum programme receives patents in Hong Kong and China

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced on Wednesday that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with the company's Aurora+FLT3 Kinase Inhibito

Read more
23 May 2016 11:06

Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
23 May 2016 11:01

*Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
17 May 2016 08:03

Sareum Appoints Silence Therapeutics' Stephen Parker As Chairman

Read more
5 Apr 2016 12:33

Sareum cancer drug candidate gets MHRA trial approval

(ShareCast News) - Sareum Holdings was pressing ahead with one of its cancer drug programmes on Tuesday, having received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the Clinical Trial Applications submitted for CHK1 inhibitor drug candidate CCT245737. The AIM-tra

Read more
5 Apr 2016 09:46

Sareum Holdings Gets Clinical Trial Approval For Cancer Drug Candidate

Read more
24 Mar 2016 12:03

Sareum Raises GBP1.1 Million For Drug Development Programmes (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.